Ex vivo activation of tumor-draining lymph node T cells reverses defects in signal transduction molecules

Cancer Immunology Immunotherapy

Volumn 46, Issue 5, 1998, Pages 268-276

  Liu, Jim ^a   Finke, James ^a   Krauss, John C ^a   Shu, Suyu ^a   Plautz, Gregory E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Adoptive immunotherapy; Signal transduction; T lymphocytes

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN TYROSINE KINASE;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SUBSTRATE; FEMALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES; ANTIGENS, CD3; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; LYMPH NODES; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK); MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NF-KAPPA B; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-FYN; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSLOCATION, GENETIC;

EID: 0031874104     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050487     Document Type: Article

References (42)

1. Alexander JP, Kudoh S, Melsop KA, Hamilton TA, Edinger MG, Tubbs RR, Sica D, Tuason L, Klein E, Bukowski RM, Finke JH (1993) T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res 53:138
2. Area MJ, Krauss JC, Aruga A, Cameron MJ, Shu S, Chang AE (1996) Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. Cancer Gene Ther 3:39
3. Area MJ, Krauss JC, Strome SE, Cameron MJ, Chang AE (1996) Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes. Cancer Immunol Immunother 42:237
4. Baeurle PA, Henkel T (1994) Function and activation of NF-κB in the immune system. Annu Rev Immunol 12:141
5. Borberg H, Oettgen HF, Chondry F, Beattie EJ Jr (1972) Inhibition of established transplants of chemically induced sarcomas in syngeneic mice by lymphocytes from immunized donors. Int J Cancer 10:539
6. Bours V, Franzoso G, Brown K, Park S, Azarenko V, Tomita-Yamaguchi M, Kelly K, Siebenlist U (1992) Lymphocyte activation and the family of NF-κB transcription factor complexes. Curr Top Microiol Immunol 182:411
7. fyn). Cell 65:281
8. Fefer A (1969) Immunotherapy and chemotherapy of Moloney sarcoma virus-induced tumors in mice. Cancer Res 29:2177
9. lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 53:5613
10. Franco JL, Ghosh P, Wiltrout RH, Carter CRD, Zea AH, Momozaki N, Ochoa AC, Longo DL, Sayers TJ, Komschlies KL (1995) Partial degradation of T-cell signal transduction molecules by contaminatint granulocytes during protein extraction of splenic T cells from tumor-bearing mice. Cancer Res 55:3840
11. fyn-mediated signal transduction on T cell activation. Int Immunol 6:1245
12. Ghosh P, Sica A, Young HA, Ye J, Franco JL, Wiltrout RH, Longo DL, Rice NR, Komschlies KL (1994) Alterations in NFKB/Rel family proteins in splenic T-cells from tumor-bearing mice and reversal following therapy. Cancer Res 54:2969
13. Hersh EM, Taylor CW (1991) Immunotherapy by active immunization: use of nonspecific stimulants and immunomodulators. In: DeVita VT, Hellman S, Rosenberg SA (eds) Biologic therapy of cancer. Lippincott, Philadelphia, p 613
14. Inoue M, Plautz GE, Shu S (1996) Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells. Cancer Res 564:702
15. Iwashima M, Irving BA, van Oers NSC, Chan AC, Weiss A (1994) Sequential interactions of the TCR with two distinct cytoplasmic tyrosine kinases. Science 263:1136
16. Jaeger E, Bernhard H, Romero P, Ringhoffer M, Arand M, Karbach J, Ilsemann C, Hagedorn M, Knuth A (1996) Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanomaassociated antigens. Int J Cancer 66:162
17. Kagamu H, Touhalisky JE, Plautz GE, Krauss JC, Shu S (1996) Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes. Cancer Res 56:4338
18. Li X, Liu J, Park J-K, Hamilton TA, Rayman P, Klein E, Edinger M, Tubbs R, Bukowski R, Finke J (1994) T cells from renal cell carcinoma patients exhibit an abnormal pattern of κB-specific DNA-binding activity: a preliminary report. Cancer Res 54:5424
19. + T cells. J Immunol 149:949
20. Miescher S, Whiteside TL, Carrel C, Von Fliedner V (1986) Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol 136:1899
21. Miescher SM, Stoeck L, Qiao L, Barras C, Barrelet L, Von Fliedner V (1988) Proliferative and cytolytic potentials of purified human tumor-infiltrating T lymphocytes. Int J Cancer 42:659
22. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC (1992) Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258:1795
23. Nabel GJ, Nabel EG, Yang Z-Y, Fox BA, Plautz GE, Gao X, Huang L, Shu S, Gordon D, Chang AE (1993) Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 90:1307
24. Peng L, Shu S, Krauss JC (1997) Treatment of subcutaneous tumor with adoptively transferred T cells. Cell Immunol 178:24
25. Prehn RT, Main JM (1957) Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 18:769
26. Rosenau W, Morton DL (1966) Tumor-specific inhibition of growth of methylcholanthrene-induced sarcomas in vivo and in vitro by sensitized isologous lymphoid cells. J Natl Cancer Inst 36:826
27. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, et al. (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastic cancer. N Engl J Med 313:1485
28. Rosenberg SA, Lotze MT, Yang JC (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210:474
29. Salvadori S, Zier K (1996) Molecular basis of T cell dysfunction in cancer is influenced by the paracrine secretion of tumor-derived IL-2. J Immunol 156:2927
30. Salvadori S, Gansbacher B, Pizzimenti AM, Zier KS (1994) Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2-secreting tumors. J Immunol 153:5176
31. Samelson LE, Phillips AF, Luong ET, Klausner RD (1990) Association of the fyn protein-tyrosine kinase with the T-cell antigen receptor. Proc Natl Acad Sci USA 87:4358
32. Schreiber E, Matthias P, Muller MM, Schaffner W (1989) Rapid detection of octamer binding proteins with "mini-extracts" prepared from a small number of cells. Nucleic Acids Res 17:6419
33. Shu S, Chou T, Rosenberg SA (1987) Generation from tumor-bearing mice of lymphocytes with in vitro therapeutic efficacy. J Immunol 139:295
34. Shu S, Krinock RA, Matsumura T, Sussman JJ, Fox BA, Chang AE, Terman DS (1994) Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells. J Immunol 152:1277
35. Smith HG, Harmel RP, Hanna MG Jr, Zwillig BS, Zhar B, Rapp HJ (1977) Regression of established intradermal tumors and lymph node metastases in guinea pigs after systemic transfer of immune lymphoid cells. J Natl Cancer Inst 58:1315
36. Straus DB, Weiss A (1992) Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor. Cell 70:585
37. Wahl WL, Sussman JJ, Shu S, Chang AE (1994) Adoptive immunotherapy of murine intracerebral tumors with anti-CD3/ Interleukin-2-activated tumor-draining lymph node cells. J Immunother 15:242
38. Wang Q, Stanley J, Kudoh S, Myles J, Kolenko V, Yi T, Tubbs RR, Bukowski RM, Finke JH (1995) T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3 associated kinases are present. J Immunol 155:1382
39. Weiss A, Littman DR (1994) Signal transduction by lymphocyte antigen receptors. Cell 76:263
40. Wespic HT, Zbar B, Rapp HJ, Borsos T (1970) Systemic transfer of tumor immunity: delayed hypersensitivity and suppression of tumor growth. J Natl Cancer Inst 44:955
41. Wiggington JM, Komschlies KL, Green JE, Cox GW, Jorcyk CL, Back TC, Franco JL, Brunda MJ, Wiltrout RH (1996) Evaluation of the untitumor activity of the interleukin-12/pulse interleukin-2 combination. Ann NY Acad Sci USA 795:434
42. Yoshizawa H, Chang AE, Shu S (1991) Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol 147:729